New Insights into Autism and the Immune System

Key Findings and Implications

The study identified elevated levels of inflammatory markers like IL-18 and adhesion molecules such as ICAM-1 and MADCAM1, which facilitate immune cell movement between the blood and brain. To delve deeper into these findings, we spoke with Attila Szabo and Sigrun Hope about the implications for autism research and potential future treatments.

Exploring Inflammasome Activation

Attila Szabo begins by grounding the research in a rising need to understand ASD further, noting the disorder’s increasing prevalence and its link to inflammation.

– ASD is a neurodevelopmental disorder with a rising incidence, and the negative influence of inflammation on neurodevelopment is well documented. Our study builds on over four decades of research linking the immune system to ASD, revealing abnormalities at the cellular and systemic levels. However, these findings are purely exploratory at this stage.

Sigrun Hope, one of the multiple co-authors, highlights the long history of research linking the immune system to ASD:

– The initial evidence linking the immune system to ASD was published over four decades ago (Stubbs and Crawford, 1977), and several preclinical and clinical studies have since revealed potential pathomechanisms and associated neuro-immune connections at both cellular and systemic levels in ASD (Goines and Van de Water, 2010; Meltzer and Van de Water, 2017).

She further elaborates on the broader implications of their findings by mentioning potential pathophysiological pathways.

– The inflammasome functions as a link between psychological stress, depression, and systemic illnesses (Iwata et.al.). This underscores the complexity and interconnectedness of factors influencing ASD. Moreover, oxytocin modulates the immune system, as seen in studies like the one from 2019 (Inoue et. al.), which demonstrated its ability to suppress inflammatory responses.

Clinical Implications and Future Directions

Sigrun Hope further elaborates on what their study could mean in guiding future research, suggesting potential long-term benefits for those with ASD.

– The study suggests that ASD patients may eventually benefit from treatments targeting comorbid inflammatory diseases and reducing stress, but these are long-term prospects. More importantly, it lays a foundation for future research into novel therapies that modulate immune functions. These findings provide a roadmap for more targeted future research efforts but are not applicable for immediate clinical use.

Attila Szabo picks up on the theme of careful forward planning, emphasizing the cautious approach required for any potential therapeutic applications arising from their research.

– By addressing immune dysregulation and its impact on symptoms, we aim to open doors for enhancing the quality of life for those with autism in the future. While promising, the results are preliminary and require extensive further research before any safe and effective applications can be developed.

Translating Findings into Treatments

In wrapping up the discussion, both researchers acknowledge the continued need for exploration and careful testing before translating findings into practice. Hope stresses the importance of understanding the varied presentations and subgroup nuances within ASD for effectively tailoring therapies.

– Understanding the mechanisms and potential subgroup differences in ASD is crucial. As a spectrum disorder, ASD presents varied forms and symptoms, and future therapies could have different impacts across subgroups. These questions will have to be pursued in future studies.

Finally, Szabo reminds us of the significant hurdles that accompany the shift from lab discoveries to clinical settings.

– Bringing these findings from the lab to the clinic involves significant challenges. Ensuring the safety and effectiveness of any new treatments is essential, requiring rigorous testing and further research. Our goal is to build a foundation upon which future, evidence-based therapies can be safely developed.

References

1. Stubbs EG, Crawford ML. Association of the brainstem with autism. J Autism Child Schizophr. 1977;7(2):203-215.
2. Goines P, Van de Water J. The immune system’s role in the biology of autism. Curr Opin Neurol. 2010;23(2):111-117.
3. Meltzer A, Van de Water J. The role of the immune system in autism spectrum disorder. Neuropsychopharmacology. 2017;42(1):284-298.
4. Iwata M, Ota KT, Duman RS. The inflammasome: Pathway linking psychological stress, depression, and systemic illnesses. J Neuroinflammation. 2013;10(1):1-10.
5. Inoue T, Kimura T, Azuma J, Kamigaichi R, Kuroda Y. Oxytocin and its effect on immune system suppression. Cells. 2019;8(6):527.

Contacts

• Attila Szabo, Researcher
• Sigrun Hope, Researcher and Senior Consultant
• Terje Nærland, Head of Center, K.G. Jebsen Center for Neurodevelopmental disorders